Trevena (NASDAQ:TRVN) Coverage Initiated by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Trevena (NASDAQ:TRVN) in a report issued on Saturday. The firm issued a sell rating on the biopharmaceutical company’s stock.

Trevena Stock Performance

TRVN opened at $4.01 on Friday. Trevena has a one year low of $3.35 and a one year high of $25.75. The company has a market cap of $73.55 million, a P/E ratio of -1.50 and a beta of 1.03. The business’s 50-day simple moving average is $2.72 and its 200-day simple moving average is $1.20.

Trevena (NASDAQ:TRVN) last announced its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.01) EPS for the quarter, beating the consensus estimate of ($0.37) by $0.36. The company had revenue of $0.33 million during the quarter.

Hedge Funds Weigh In On Trevena

An institutional investor recently bought a new position in Trevena stock. Armistice Capital LLC bought a new stake in Trevena, Inc. (NASDAQ:TRVN) in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 797,714 shares of the biopharmaceutical company’s stock, valued at approximately $576,000. Armistice Capital LLC owned 4.61% of Trevena as of its most recent SEC filing. Institutional investors own 13.56% of the company’s stock.

About Trevena

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.